UNSPSC 51101929: Docetaxel

This classification denotes a taxane compound and taxane-site binding agent with the molecular formula C43H53NO14.3H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 15H5577CQD, chemically known as docetaxel, anhydrous but generally known as docetaxel, which bears US NIH Compound Identifier 64780. European Medicines Agency schedules Docetaxel in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12492MIG.

UNSPSC 51101929 Docetaxel is a Commodity code nominally identifying a specific chemotherapy agent, but recent state and local procurement activity tagged to this code does not reflect oncology pharmaceutical purchases. Instead, the code appears in solicitations for emergency medical supplies, naloxone, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals — a mismatch suggesting either misclassification in the source data or a broader catch-all use of the code for pharmaceutical and medical supply procurement generally. The actual work being solicited under this code spans emergency response consumables (respiratory equipment, cardiac monitoring electrodes, bandaging materials), opioid-reversal agents and drug deactivation systems, generic pharmaceutical distribution arrangements, and therapeutic pharmacy initiatives. Issuing bodies include county health departments (Seminole County, Florida), municipal fire and rescue services (City of Tampa), state health and human services agencies (Texas HHS Commission), and cooperative purchasing alliances serving multiple state and local jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance). The mix reflects fragmented buying across public health, emergency medical services, and pharmacy benefit administration rather than concentrated procurement within a single service line.

Recent activity spans Florida, Texas, Minnesota, and Oregon across January through June 2026. The Seminole County Community Health Building issued an IFB on June 30, 2026 (due July 26, 2023, per the source) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries at an estimated contract value of approximately $700,000 annually. The City of Tampa issued an IFB in March 2026 for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division, with a contract value of $700,000 and a five-working-day delivery requirement; this solicitation was designated a sheltered market opportunity for certified Small Local Business Enterprises with a 5 percent bid discount not to exceed $10,000. The Minnesota Multistate Cooperative Purchasing Alliance released an RFP in January 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products across state and local facilities in Minnesota and Oregon, requiring products to be available by May 15, 2026 and effective July 1, 2026 through authorized wholesalers. The Texas HHS Commission issued an RFI in April 2026 seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, indicating early-stage market research rather than a competitive procurement.